Back to top
more

Pliant Therapeutics (PLRX)

(Delayed Data from NSDQ)

$14.49 USD

14.49
505,444

-0.03 (-0.21%)

Updated Nov 4, 2024 04:00 PM ET

After-Market: $14.52 +0.03 (0.21%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Earnings Preview: Pliant Therapeutics, Inc. (PLRX) Q4 Earnings Expected to Decline

by Zacks Equity Research

Pliant Therapeutics, Inc. (PLRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Is a Surprise Coming for Pliant Therapeutics (PLRX) This Earnings Season?

by Zacks Equity Research

Pliant Therapeutics (PLRX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Pliant Therapeutics, Inc. (PLRX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

by Zacks Equity Research

Pliant Therapeutics, Inc. (PLRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Biotech Stock Roundup: ICPT Up on Buyout Deal, IMVT & PLRX Gain on Study Data

by Zacks Equity Research

Acquisition news from Intercept (ICPT) and study updates from Immunovant (IMVT) are in focus in the biotech sector.

Pliant (PLRX) Up on Success of Mid-Stage Liver Disease Study

by Zacks Equity Research

Pliant's (PLRX) phase II study on lead pipeline candidate bexotegrast, achieves its primary and secondary endpoints. Shares rise

Pliant Therapeutics, Inc. (PLRX) Soars 14.3%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Pliant Therapeutics, Inc. (PLRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Pliant Therapeutics, Inc. (PLRX) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Pliant Therapeutics, Inc. (PLRX) delivered earnings and revenue surprises of 4.11% and 77.46%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Acadia Pharmaceuticals (ACAD) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Acadia (ACAD) delivered earnings and revenue surprises of 108.33% and 7.08%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Vertex Pharmaceuticals (VRTX) Q2 Earnings and Revenues Top Estimates

by Zacks Equity Research

Vertex (VRTX) delivered earnings and revenue surprises of 1.04% and 3.47%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Pliant Therapeutics, Inc. (PLRX) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Pliant Therapeutics, Inc. (PLRX) delivered earnings and revenue surprises of -1.52% and 31.87%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Cardiff Oncology (CRDF) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Cardiff Oncology (CRDF) delivered earnings and revenue surprises of -8.70% and 10.67%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Pliant Therapeutics, Inc. (PLRX) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Pliant Therapeutics, Inc. (PLRX) delivered earnings and revenue surprises of -2.86% and 27.10%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Codexis (CDXS) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Codexis (CDXS) delivered earnings and revenue surprises of 17.39% and 4.30%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Techne (TECH) Q2 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Techne (TECH) delivered earnings and revenue surprises of -4.08% and 6.34%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Biotech Stock Roundup: BLUE Down on Share Issuance, CPRX Falls on Generic Filing & More

by Zacks Equity Research

Updates from bluebird (BLUE) and Catalyst Pharmaceuticals (CPRX) are the key highlights from the biotech sector during the past week.

Pliant Therapeutics (PLRX) Surges 44% in A Week: Here's Why

by Zacks Equity Research

Shares of Pliant Therapeutics (PLRX) have been rising since management reported positive interim data from a mid-stage study evaluating a higher dose of its lead pipeline candidate in IPF patients.

Strength Seen in Pliant Therapeutics, Inc. (PLRX): Can Its 8.3% Jump Turn into More Strength?

by Zacks Equity Research

Pliant Therapeutics, Inc. (PLRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Pliant Therapeutics, Inc. (PLRX) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Pliant Therapeutics, Inc. (PLRX) delivered earnings and revenue surprises of 12.16% and 34.43%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Codexis (CDXS) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Codexis (CDXS) delivered earnings and revenue surprises of 16.67% and 9.74%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Is Assertio (ASRT) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Assertio (ASRT) and Pliant Therapeutics, Inc. (PLRX) have performed compared to their sector so far this year.

AVEO Pharmaceuticals (AVEO) Inks Deal to be Acquired by LG Chem

by Zacks Equity Research

Aveo Pharmaceuticals (AVEO) is set to be acquired by LG Chem for an aggregate amount of $566 billion. The deal is expected to close by early 2023. Stock up.

Milestone's (MIST) Tachycardia Study Data Fail to Impress Investors

by Zacks Equity Research

Milestone (MIST) reports positive top-line results from its late-stage study evaluating its lead candidate, etripamil, in patients with paroxysmal supraventricular tachycardia. The results fail to impress investors.

Emergent (EBS) Initiates Study on Lassa Virus Vaccine Candidate

by Zacks Equity Research

Emergent BioSolutions (EBS) initiates an early-stage study evaluating its Lassa virus vaccine candidate, EBS-LASV, for the prevention of Lassa fever.

Axsome (AXSM) up 118.4% in the Past Three Months: Here's Why

by Zacks Equity Research

Axsome (AXSM) surges in the past three months owing to its Sunosi acquisition and promising progress on its pipeline candidate.

Has Pliant Therapeutics (PLRX) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Pliant Therapeutics, Inc. (PLRX) and Alaunos (TCRT) have performed compared to their sector so far this year.